Advances in stem cell research for the treatment of primary hypogonadism.
Level 5 - mechanism / opinion, no new human data
Narrative review without primary human trial data
PubMed 34188209 · doi:10.1038/s41585-021-00480-2
What was done
This narrative review summarizes developments over the past two decades in stem-cell-based strategies for treating primary hypogonadism, focusing on the derivation of Leydig-like cells from stem Leydig cells, mesenchymal stem cells, and pluripotent stem cells (PSCs).
What was found
The abstract reports no numerical findings. It outlines the clinical limitations of standard testosterone replacement therapy—specifically secondary infertility, erythrocytosis, gynaecomastia, exacerbation of obstructive sleep apnoea, and cardiovascular risks—and reviews the development of PSC-derived Leydig-like cells as in vitro differentiation models and candidates for cell-based transplantation.
Why it matters
Cell-based restoration of Leydig cell function represents a potential regenerative alternative to lifelong exogenous testosterone replacement that could avoid drug-induced suppression of fertility.
Limits
This is a non-systematic narrative review of preclinical and in vitro literature; it provides no original human data, sample sizes, clinical trial outcomes, or quantitative synthesis.
Cited by
- supports Luteinizing hormone (LH) from the pituitary gland signals Leydig cells in the testes to produce testosterone.
- supports Primary hypogonadism cannot be treated or resolved with clomiphene, hCG, or hMG because the testes cannot produce testosterone in response to signaling.